Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790378 | Urologic Oncology: Seminars and Original Investigations | 2017 | 8 Pages |
Abstract
Although less than one-third of SRT patients from the study era received ADT, there is evidence that physicians and patients have begun slowly adopting this practice with the 2010 reporting of a decrease in the cumulative incidence of metastases with the addition of ADT to SRT. Given the newly reported survival benefit of RTOG 9601, additional work will be necessary to identify which patients benefit the most from the use of ADT with SRT to individualize treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
David D. B.A., Vinayak M.D., M.Sc., Brandon A. M.D., Michelle D. B.A., Shelby A. B.S., Marie E. B.S., Ninjin M.P.H., Martin T. M.D., Ph.D., Neil E. M.D., M.P.H., Peter F. D.O., M.S., Tni K. M.D., Quoc-Dien M.D., Robert B. M.D., Daniel E. M.D.,